Association Between Pharmacy Benefit Restrictions and Disease-Modifying Therapy Use in the Medicare Part D Program.

Hartung, Daniel M; Johnston, Kirbee A; McGregor, Jessina C; Bourdette, Dennis N

Hartung, Daniel M; Johnston, Kirbee A; McGregor, Jessina C; Bourdette, Dennis N.

Afiliação

Hartung DM; College of Pharmacy (DMH, KAJ, JCM), Oregon State University; and Department of Neurology (DNB), Oregon Health & Science University, Portland.
Johnston KA; College of Pharmacy (DMH, KAJ, JCM), Oregon State University; and Department of Neurology (DNB), Oregon Health & Science University, Portland.
McGregor JC; College of Pharmacy (DMH, KAJ, JCM), Oregon State University; and Department of Neurology (DNB), Oregon Health & Science University, Portland.
Bourdette DN; College of Pharmacy (DMH, KAJ, JCM), Oregon State University; and Department of Neurology (DNB), Oregon Health & Science University, Portland.

Neurol Clin Pract ; 12(1): 36-42, 2022 Feb.

Article em En | MEDLINE | ID: mdl-36157618

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Revista: Neurol Clin Pract Ano de publicação: 2022 Tipo de documento: Article País de publicação: Estados Unidos

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google